There is no FDA-approved dose for DSIP. The peptide is not a regulated medicine, and the dosing information you find online comes from a mix of published research (mostly pre-1990), forum protocols, and vendor marketing copy. Those sources don’t agree, and the gaps reflect real gaps in evidence.<\/p>\n
This page walks through the doses that have appeared in published human trials, the protocols circulating in peptide forums, what’s known about pharmacokinetics, and the practical risks of choosing a dose without medical supervision.<\/p>\n
If you’re considering DSIP, your first question shouldn’t be “what dose” but “what evidence.” This guide gives you both.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Schneider-Helmert’s 1986 Pharmacopsychiatry study used 25 nmol\/kg intravenously in chronic insomniacs.<\/strong> For an 80 kg patient, that’s 2 micromoles, or about 1.7 mg of DSIP given the molecular weight of 849 daltons. The infusion was given over 5 to 15 minutes.<\/p>\n Quick Answer: Published human studies used 25 to 60 nmol\/kg intravenously (roughly 1.7 to 4 mg per dose for an 80 kg adult)<\/p>\n Other studies in the 1980s used doses ranging from 25 to 60 nmol\/kg IV. Larbig and colleagues in a 1984 European Journal of Pharmacology paper tested intranasal DSIP at approximately 0.1 mg per dose for chronic pain. Subcutaneous administration was not used in any major published human trial.<\/p>\n The published doses are higher than what vendors typically recommend for subcutaneous use. That gap reflects different routes of administration and bioavailability, but it also reflects the absence of dose-response studies for the subcutaneous route. Nobody has done the work to translate IV dosing to SC dosing in a rigorous way.<\/p>\n Peptide forums and vendor websites typically recommend 100 to 500 micrograms of DSIP subcutaneously, injected before bed.<\/strong> Some protocols suggest daily dosing, others suggest cycling with two to three weeks on and one to two weeks off.<\/p>\n These numbers come from anecdotal user reports rather than controlled trials. The forum culture that produced them has the same problems as any uncontrolled self-report: confirmation bias, placebo effects, selection bias toward people who had any effect, and survivorship bias toward people still posting after months of use.<\/p>\n A 100 microgram subcutaneous dose is roughly one-twentieth of a published IV dose. Whether subcutaneous administration achieves equivalent brain concentrations is unknown because the pharmacokinetic studies haven’t been done. The dose could be too low to do anything or could produce different effects than IV dosing.<\/p>\n Plasma half-life is short.<\/strong> Studies from the 1980s using radiolabeled DSIP showed clearance from circulation within 7 to 15 minutes after IV administration. Peptidases in blood and tissues break the molecule down rapidly.<\/p>\n Brain levels rise and fall more slowly than plasma levels, but still on a timescale of an hour or less. Despite this, effects on sleep architecture reported in some studies persisted for days to weeks after dosing ended. That mismatch is one of the unresolved puzzles in DSIP research.<\/p>\n For practical dosing, the short half-life suggests timing matters: if DSIP has acute effects, they would occur within an hour of administration, not throughout the night. This argues against the idea of DSIP as a sustained sleep maintainer in the way that extended-release zolpidem or trazodone work.<\/p>\n There is no established cycling protocol in peer-reviewed literature.<\/strong> Vendor and forum protocols often suggest cycles, typically two to three weeks on followed by one to two weeks off, but the rationale is vague.<\/p>\n For some peptides, cycling is suggested to prevent receptor desensitization. Since DSIP has no identified receptor, this rationale doesn’t really apply. Other peptides are cycled to limit cost or to avoid unknown long-term effects. Those are reasonable considerations for any compound with limited safety data.<\/p>\n Schneider-Helmert’s data suggested DSIP effects persisted for weeks after a short dosing period. If that’s true, daily dosing may not be necessary even if DSIP does have real effects. Spacing doses widely could make sense from a pharmacological standpoint, though again, the data to support specific schedules don’t exist.<\/p>\n Forum protocols universally recommend evening dosing, typically 30 to 60 minutes before bed.<\/strong> The rationale is matching the timing of natural delta-wave sleep, which occurs primarily in the first third to half of the night.<\/p>\n Published human studies have used both daytime and evening dosing. Some intravenous administration occurred during clinical hours for monitoring purposes, with sleep recorded overnight. No comparison of evening versus other timing has been published.<\/p>\n If you’re going to use DSIP, evening administration seems reasonable given the claimed effects. There’s no evidence to support claims about specific optimal timing within the evening window.<\/p>\n Key Takeaway: DSIP plasma half-life is 7 to 15 minutes; brain effects appear to outlast peripheral clearance<\/p>\n Melatonin doses in published studies range from 0.3 mg to 10 mg orally, with most evidence supporting doses of 0.5 to 3 mg for sleep onset.<\/strong> That’s a well-characterized dose-response relationship from dozens of placebo-controlled trials.<\/p>\n Zolpidem (Ambien) is dosed at 5 to 10 mg oral, FDA-approved with extensive pharmacokinetic and dose-response data. Trazodone is used off-label for sleep at 25 to 100 mg.<\/p>\n DSIP has no comparable evidence base for dose selection. The available doses are essentially guesses informed by a few small studies and a lot of forum speculation. That’s a different category of evidence.<\/p>\n Reported side effects from published studies at 25 to 60 nmol\/kg IV include mild headache, transient nausea, and occasional dizziness.<\/strong> No serious adverse events were reported, but total exposed populations across published studies are probably under 200 people.<\/p>\n At the lower subcutaneous doses used in forum protocols (100 to 500 micrograms), side effect reports anecdotally include injection site reactions, vivid dreams, daytime grogginess in some users, and occasional headache. These are user reports, not controlled trial data.<\/p>\n Long-term effects are entirely unstudied. Effects on hormonal axes, immune function, cognitive function, or chronic disease risk over years of use have no data. Anyone using DSIP chronically is essentially participating in an uncontrolled experiment.<\/p>\n This is a real issue.<\/strong> Research chemical vendors and gray-market peptide suppliers vary widely in quality control. Independent testing of peptide products has repeatedly found mislabeled potency, bacterial endotoxin contamination, and presence of related but distinct peptide impurities.<\/p>\n A 2020 paper in Drug Testing and Analysis examined growth hormone secretagogue products sold online and found significant discrepancies between labeled and actual content. Similar systematic studies haven’t been done for DSIP specifically, but the production and supply chain issues are the same.<\/p>\n Reconstitution with bacteriostatic water, sterile injection technique, and refrigerated storage are minimum handling requirements. Endotoxin contamination from poor manufacturing can cause fever and other systemic reactions even at low peptide doses.<\/p>\n Medically supervised peptide therapy through licensed compounding pharmacies has dramatically better quality controls.<\/strong> Pharmacies registered with state boards face inspections, USP standards for sterile compounding, and documented chain of custody from raw material to finished product.<\/p>\n For peptides with real clinical indications, this is the safety floor. TrimRx works in this regulated space for compounded semaglutide and tirzepatide, where the active ingredients are FDA-approved and the compounding standards are clear. The free assessment quiz and personalized treatment plans run within this regulatory framework.<\/p>\n For experimental peptides like DSIP, even medically supervised compounding faces evidence gaps. The dose, schedule, and indications aren’t established. Some prescribers will compound DSIP off-label; quality of preparation is still better than gray-market sources, but the underlying clinical evidence remains thin.<\/p>\n Bottom line: Quality and purity of vendor-supplied DSIP varies widely without third-party testing<\/p>\n There is no established safe starting dose. Forum protocols typically suggest starting at 100 micrograms subcutaneously and titrating up, but no controlled data supports specific titration schedules. The honest answer is that any dose is partly a guess.<\/p>\n No data supports either approach over the other. Persistent effects reported in some studies suggest occasional dosing might be sufficient. Daily dosing has no evidence-based justification beyond what users report subjectively.<\/p>\n No withdrawal syndrome has been described in published literature. The peptide is not known to cause physical dependence, but the lack of evidence reflects small sample sizes rather than confirmed safety.<\/p>\n Yes, with proper sterile technique and refrigerated storage. Reconstituted peptide solutions typically remain stable for 14 to 30 days refrigerated, depending on the specific peptide and reconstitution diluent.<\/p>\n Lyophilized (freeze-dried) peptide should be stored frozen until reconstitution. Once mixed with bacteriostatic water, store refrigerated and protect from light. Discard if the solution becomes cloudy or discolored.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" There is no FDA-approved dose for DSIP.<\/p>\n","protected":false},"author":11,"featured_media":92758,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"DSIP (Delta Sleep-Inducing Peptide) Dosing Protocol: Cycling, Frequency & Best Practices","_yoast_wpseo_metadesc":"There is no FDA-approved dose for DSIP. The peptide is not a regulated medicine, and the dosing information you find online comes from a mix of...","_yoast_wpseo_focuskw":"dsip dosing protocol","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[19],"tags":[25,40],"class_list":["post-89459","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-longevity","tag-dosing","tag-peptides"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89459","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89459"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89459\/revisions"}],"predecessor-version":[{"id":92381,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89459\/revisions\/92381"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92758"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89459"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89459"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89459"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Do Online Protocols Actually Recommend?<\/h2>\n
How Long Does DSIP Stay Active?<\/h2>\n
Should DSIP Be Cycled?<\/h2>\n
What Time of Day Should You Take DSIP?<\/h2>\n
How Does DSIP Dosing Compare to Melatonin or Other Sleep Aids?<\/h2>\n
What Are the Practical Safety Considerations at Typical Doses?<\/h2>\n
What About Quality and Purity of Vendor-supplied DSIP?<\/h2>\n
How Does This Compare to Medically Supervised Peptide Therapy?<\/h2>\n
FAQ<\/h2>\n
What’s a Safe Starting Dose If I’m Going to Try DSIP?<\/h3>\n
Should DSIP Be Taken Every Night or Only When Needed?<\/h3>\n
What Happens If You Miss a Dose or Stop Suddenly?<\/h3>\n
Can You Split a Vial Across Multiple Doses?<\/h3>\n
How Do You Store DSIP?<\/h3>\n